JP2020505440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505440A5 JP2020505440A5 JP2019557669A JP2019557669A JP2020505440A5 JP 2020505440 A5 JP2020505440 A5 JP 2020505440A5 JP 2019557669 A JP2019557669 A JP 2019557669A JP 2019557669 A JP2019557669 A JP 2019557669A JP 2020505440 A5 JP2020505440 A5 JP 2020505440A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- compound according
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 2
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims 1
- -1 1,4-dioxepanyl Chemical group 0.000 claims 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000005879 dioxolanyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 0 CC*(C)C(C(N=O)=O)=CC Chemical compound CC*(C)C(C(N=O)=O)=CC 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710017287.2 | 2017-01-10 | ||
| CN201710017287 | 2017-01-10 | ||
| PCT/CN2018/072088 WO2018130155A1 (zh) | 2017-01-10 | 2018-01-10 | Hdac6选择性抑制剂及其制备方法和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505440A JP2020505440A (ja) | 2020-02-20 |
| JP2020505440A5 true JP2020505440A5 (enExample) | 2021-02-18 |
| JP7237010B2 JP7237010B2 (ja) | 2023-03-10 |
Family
ID=62839715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557669A Active JP7237010B2 (ja) | 2017-01-10 | 2018-01-10 | Ｈｄａｃ６選択的阻害剤およびその製造方法と使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10745389B2 (enExample) |
| EP (1) | EP3569592B8 (enExample) |
| JP (1) | JP7237010B2 (enExample) |
| KR (1) | KR102549606B1 (enExample) |
| CN (1) | CN110382463B (enExample) |
| AU (1) | AU2018208160B2 (enExample) |
| ES (1) | ES2927352T3 (enExample) |
| IL (1) | IL267968B (enExample) |
| MX (1) | MX394624B (enExample) |
| SA (1) | SA519402090B1 (enExample) |
| SG (1) | SG11201906361YA (enExample) |
| WO (1) | WO2018130155A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11345682B2 (en) | 2018-07-04 | 2022-05-31 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Polymorph of HDAC6-selective inhibitor and application thereof |
| BR112021026334A2 (pt) | 2019-06-27 | 2022-05-10 | Medstar Health | Macrófagos ativados por hdac6, composições, e usos dos mesmos |
| WO2021110121A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Hdac6选择性抑制剂及其组合疗法 |
| CN114980887A (zh) | 2019-12-20 | 2022-08-30 | 特纳亚治疗股份有限公司 | 氟代烷基-噁二唑及其用途 |
| IL307883A (en) | 2021-04-23 | 2023-12-01 | Tenaya Therapeutics Inc | HDAC6 inhibitors for use in the treatment of dilated myocardial disease |
| WO2022235842A1 (en) | 2021-05-04 | 2022-11-10 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| WO2024123700A1 (en) * | 2022-12-05 | 2024-06-13 | The General Hospital Corporation | Histone deacetylase inhibitors |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003066889A2 (en) * | 2002-02-07 | 2003-08-14 | Axys Pharmaceuticals, Inc. | Assay for acytyltransferase or deacetylase activity |
| CN101641338A (zh) * | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | 作为抗增殖制剂的多功能小分子 |
| AU2009276699A1 (en) | 2008-07-28 | 2010-02-04 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
| WO2011106632A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| PL2640709T3 (pl) | 2010-11-16 | 2016-10-31 | Związki pirymidynohydroksyamidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania” | |
| US8404738B2 (en) * | 2011-01-21 | 2013-03-26 | Hoffmann-La Roche Inc. | 4-amino-N-hydroxy-benzamides for the treatment of cancer |
| EP2826769A1 (en) | 2013-07-18 | 2015-01-21 | Institut de Recherche pour le Développement ( IRD) | Compounds for the treatment and/or prevention of parasitic diseases and method of production thereof |
| CA2933907A1 (en) * | 2013-12-23 | 2015-07-02 | The Trustees Of Columbia University In The City Of New York | Selective hdac6 inhibitors |
| US9464073B2 (en) * | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
-
2018
- 2018-01-10 KR KR1020197022672A patent/KR102549606B1/ko active Active
- 2018-01-10 ES ES18739134T patent/ES2927352T3/es active Active
- 2018-01-10 CN CN201880006463.5A patent/CN110382463B/zh active Active
- 2018-01-10 JP JP2019557669A patent/JP7237010B2/ja active Active
- 2018-01-10 EP EP18739134.7A patent/EP3569592B8/en active Active
- 2018-01-10 US US16/476,660 patent/US10745389B2/en active Active
- 2018-01-10 MX MX2019008181A patent/MX394624B/es unknown
- 2018-01-10 WO PCT/CN2018/072088 patent/WO2018130155A1/zh not_active Ceased
- 2018-01-10 AU AU2018208160A patent/AU2018208160B2/en active Active
- 2018-01-10 SG SG11201906361YA patent/SG11201906361YA/en unknown
-
2019
- 2019-07-09 SA SA519402090A patent/SA519402090B1/ar unknown
- 2019-07-10 IL IL267968A patent/IL267968B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2328486C2 (ru) | Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы | |
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2016515561A5 (enExample) | ||
| CN112533916A (zh) | 一种作用于crbn蛋白的三并环类化合物 | |
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| JP2014507455A5 (enExample) | ||
| RU2019104899A (ru) | Ингибитор ido1 и способ его получения и применение | |
| JP2007530694A5 (enExample) | ||
| JP2013509392A5 (enExample) | ||
| CN110382463A (zh) | Hdac6选择性抑制剂及其制备方法和应用 | |
| JP2014502988A5 (enExample) | ||
| JP2014505017A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| JP2020500916A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2020511536A5 (enExample) | ||
| JP2020504184A5 (enExample) | ||
| JP2023552610A5 (enExample) | ||
| JP2016503778A5 (enExample) | ||
| JP2022526553A5 (enExample) | ||
| JP2024507414A5 (enExample) | ||
| JP2020519687A5 (enExample) | ||
| CA2539349A1 (en) | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |